INTRASPINAL INFUSION OF NMDA ANTAGONISTS FOR THE TREATMENT OFINTRACTABLE NEUROPATHIC PAIN: PRELIMINARY NEUROPATHOLOGY STUDIES NIH Guide, Volume 22, Number 15, April 16, 1993 RFP AVAILABLE: NIH-NIDR-2-93-3R P.T. 34 Keywords: Pain Treatment, Medical+ National Institute of Dental Research The National Institute of Dental Research (NIDR) has a requirement for the conduct of extensive studies in rats and, subsequently, in a larger mammal, to identify the maximum safe intrathecal dose of three NMDA antagonists, to compare the behavioral toxicity at doses giving equal pain relief, and to make certain that chronic spinal administration of the drugs does not damage the spinal cord. The drugs to be investigated are ketamine, dextrorphan, and memantine. Request for Proposals (RFP) No. NIH-NIDR-2-93-3R will be available on or about April 26, 1993, with proposals due on or about June 7, 1993. INQUIRIES Requests for the RFP must be submitted in writing, to: Marilyn R. Zuckerman Contract Management Office National Institute of Dental Research Westwood Building, Room 533 Bethesda, MD 20892 .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |